HC Wainwright Brokers Decrease Earnings Estimates for OLMA

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Olema Pharmaceuticals to a loss of $0.64 per share from $0.58, while maintaining a Buy rating and a $36 price target.
• Olema reported a Q2 loss of $0.61 per share, missing the consensus estimate of a $0.55 loss. Analysts’ consensus remains a Moderate Buy, with an average price target of $43.60.
• OLMA shares opened at $10.44, well below their 12-month high of $36.26; institutional investors own 91.78% of the company, while an insider recently sold 12,500 shares.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.64) per share for the quarter, down from their prior estimate of ($0.58). HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.44) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($2.36) EPS, FY2029 earnings at ($1.69) EPS and FY2030 earnings at ($1.03) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.06).

A number of other brokerages have also weighed in on OLMA. Weiss Ratings lowered Olema Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 3rd. Citigroup reduced their target price on Olema Pharmaceuticals to $59.00 and set a "buy" rating for the company in a report on Tuesday. Guggenheim lowered their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.60.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $10.44 on Thursday. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The business's 50 day moving average is $11.24 and its two-hundred day moving average is $15.55. Olema Pharmaceuticals has a 12-month low of $5.13 and a 12-month high of $36.26. The stock has a market capitalization of $913.50 million, a price-to-earnings ratio of -4.92 and a beta of 2.03.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently modified their holdings of OLMA. EverSource Wealth Advisors LLC raised its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company's stock valued at $31,000 after buying an additional 1,232 shares during the period. Torren Management LLC purchased a new stake in Olema Pharmaceuticals during the fourth quarter worth approximately $44,000. Russell Investments Group Ltd. purchased a new stake in Olema Pharmaceuticals during the third quarter worth approximately $53,000. American Century Companies Inc. acquired a new stake in shares of Olema Pharmaceuticals in the second quarter worth $54,000. Finally, Quantbot Technologies LP acquired a new position in shares of Olema Pharmaceuticals during the second quarter worth about $77,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Insider Buying and Selling

In other news, Director Cyrus Harmon sold 12,500 shares of the company's stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. This represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 12.56% of the stock is owned by company insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source